アンジオテンシン変換酵素と運動適応:遺伝的多様性,薬理学的調節および将来の方向性
Tórur Sjúrðarson1, Nikolai B Nordsborg2
1Centre of Health Science, Faculty of Health, University of the Faroe Islands, Tórshavn, Faroe Islands.
The Journal of physiology
|September 2, 2025
まとめ
運動 訓練 に 対する 個々 の 反応 は 様々 です. アニオテンシン変換酵素 (ACE) の活動は筋肉の成長と耐久性に影響を与えますが,ACE阻害剤は運動能力に影響しません. 精度の高い運動薬は,ACE活性を直接測定する必要があります.
科学分野:
- 運動生理学
- 薬理学について
- 遺伝学
背景:
- 運動反応の個々の変動は,運動能力と健康に影響します.
- 遺伝学や薬によって影響されるアニオテンシン変換酵素 (ACE) の活動は,運動適応において重要な役割を果たします.
研究 の 目的:
- ACE活動が骨格筋,心臓,血液の運動への適応にどのように影響するかを見直す.
- 運動の結果に対する ACE 阻害の影響を調査する.
- 訓練の多様性を理解するための将来の研究方向について議論する.
主な方法:
- ACE活動と運動適応に関する証拠を集約した文献レビュー.
- 遺伝的変異,表遺伝的調節,および薬学的ACE阻害を含む研究の分析.
- 運動によって誘発されるレニン-アニオテンシンシステムの検査
主要な成果:
- 薬学的ACE阻害は選択的に心臓および血液学的適応 (例えば,ヘモグロビン質量) を減少させるが,周辺の筋肉の適応や有酸素性能を減少させない.
- 運動はACE発現とレニン-アニオテンシンシステムのシグナリングを文脈に依存した方法で調節する.
- 遺伝子型だけでは,ACEレベルや下流信号の予測が不十分です.
結論:
- ACEは運動適応において複雑な役割を果たし,薬理学的抑制は特定の効果を有する.
- 将来の研究は,ACE活性とレニン- 血管新生系軸の直接的なフェノタイプ化に焦点を当てなければならない.
- ACE阻害は,個々のトレーニング応答の変動性を研究することによって,精密運動医学を進歩させるためのモデルとして機能します.
関連する概念動画
01:26Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
505
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
505
01:30Antihypertensive Drugs: Angiotensin-Converting Enzyme Inhibitors
871
Angiotensin-converting enzyme (ACE), a vital component of the renin-angiotensin-aldosterone system, is abundant in lung endothelial cells. ACE converts the inactive decapeptide, angiotensin I, into the active octapeptide, angiotensin II. This potent vasoconstrictor narrows blood vessels, increasing resistance to blood flow and elevating blood pressure. Angiotensin II also stimulates aldosterone production, encouraging kidney cells to reabsorb more sodium and water from urine, thereby increasing...
871
01:29Heart Failure II: Pathophysiology
37
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
37
01:30Heart Failure V: Medical Management
23
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
23
01:29Hypertension II: Pathophysiology
77
Hypertension is a chronic condition in which the blood's force against artery walls is excessively high, posing risks such as heart disease. The condition's underlying mechanisms involve complex interactions among the cardiovascular, kidney, and autonomic nervous systems.Renin-Angiotensin-Aldosterone System (RAAS): This system significantly influences blood pressure regulation. When blood pressure decreases, the kidneys secrete renin. This enzyme transforms angiotensinogen, a plasma protein,...
77
01:30Antihypertensive Drugs: Angiotensin II Receptor Blockers
911
In the renin-angiotensin-aldosterone system, a hormone called angiotensin II plays a crucial role. It binds to the AT1 receptors in vascular smooth muscles coupled with Gq proteins. The activation of these receptors activates an enzyme called phospholipase C, which releases two molecules: inositol trisphosphate and diacylglycerol. These molecules cause a chain reaction that leads to the phosphorylation of myosin light chains and promotes interaction between actin and myosin, leading to smooth...
911